Randi Hernandez

July 26, 2016

July 22, 2016

July 14, 2016

June 03, 2016.

May 26, 2016.

February 15, 2016.

January 05, 2016.

October 28, 2015.

September 25, 2015.

September 10, 2015.

August 28, 2015.

August 27, 2015.

August 12, 2015.

New cell-culture techniques, biomanufacturing formats, and the expansion of single-use applications are driving rapid change in the biopharma market.

BioPharm International speaks to the United States Pharmacopeial Convention to find out who will truly have the final say when it comes to biosimilar nomenclature.

Prescription drug usage data on more than one million Marketplace enrollees suggest that costs for specialty drugs were 36% higher for people with Obamacare.

Physician confidence in biosimilars and extrapolation of indications are two of the most important factors governing the acceptance and sustainability of biosimilars, say industry panelists.

The House Energy and Commerce Committee gave unanimous approval to the landmark 21st Century Cures Act reform bill on May 21, 2015.

Intellectual property lawyers estimate biosimilar litigation will swell as early as 2018.

The grants will be offered to investigators conducting research in the field of PCSK9 biology.

Novartis will make payments to Juno to settle a patent dispute covering chimeric antigen receptor T-cell (CAR-T) therapies.

March 16, 2015.

23 February, 2015.

Pfizer announced on Feb. 5, 2015 that it is acquiring injectable, infusible, and biosimilar manufacturer Hospira for nearly $17 billion after the assumption of debt.

GlaxoSmithKline (GSK) announced on January 26 that it will freeze vaccine prices for Gavi-eligible countries for up to 10 years after the country graduates from Gavi support.

CVS confirmed this week that it will exclusively offer Gilead's Harvoni and Sovaldi to members through its CVS/Caremark commercial, exchange, Medicare Part D, and Medicaid formularies.

The New York Times (NYT) reported on Dec. 1, 2014 that companies in the biotechnology sector might be the latest victims of computer security breaches.

The Pharmaceutical Care Management Association (PCMA), an organization that represents the nation’s leading pharmacy benefit managers (PBMs), which administer prescription drug plans for over 210 million Americans, released a new white paper investigating FDA’s influence on drug prices and competition in the pharmaceutical marketplace.

In a landmark lawsuit over the first biosimilar application, Amgen is suing Sandoz for unlawfully refusing to follow the patent resolution protocol laid out by the rules of the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension’s 1900 sites of care around the country.